What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Medical Device

In Vitro Diagnostics

PUBLISHER: Roots Analysis | PRODUCT CODE: 1771293

PUBLISHER: Roots Analysis | PRODUCT CODE: 1771293

KRAS Market: Industry Trends and Global Forecasts - Distribution by Type of Indication, Type of Molecule, Type of Therapy, Route of Administration and Key Geographical Regions

PUBLISHED: July 15, 2025

PAGES: 131 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

GLOBAL KRAS MARKET: OVERVIEW

As per Roots Analysis, the global KRAS market valued at USD 73 million in the current year is expected to grow at a CAGR of 53.6% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Indication

Acute Myeloid Leukemia
Colorectal Cancer
Head and Neck Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Phelan-McDermid Syndrome
Skin Cancer

Type of Molecule

Biologic
Small Molecule

Type of Therapy

Monotherapy
Combination Therapy

Route of Administration

Intravenous
Intramuscular
Intradermal
Intraocular
Intraperitoneal
Oral
Subcutaneous

Key Geographical Regions

North America
Europe
Asia-Pacific
Middle East and North Africa
Latin America

GLOBAL KRAS MARKET: GROWTH AND TRENDS

Cancer is considered to be the second leading cause of mortality, after cardiovascular diseases, accounting for every sixth reported death in the world. The International Agency for Research on Cancer (IARC) states that the number of new cancer cases is expected to grow to 27.5 million across the globe, by 2040. A major factor contributing to the high mortality rate associated with this condition is the tendency for late diagnosis, which in turn delays treatment and significantly reduces the patient's chances of survival.

Given that conventional therapies have been unable to exhibit significant efficacy in the treatment of RAS mutated cancers, novel drugs, specifically targeting the RAS gene, have emerged as a promising alternative. In fact, drug developers in this field are increasingly focusing on creating therapies that target specific oncogenic mutations primarily responsible for the onset and progression of the disease. Notably, RAS which was once considered to be an undruggable target, has been linked to 30% of human cancer. Over the years, numerous drug candidates have been investigated to specifically target RAS-mutated genes. Additionally, driven by encouraging clinical trial results, substantial financial assistance, and growing demand for targeted therapeutic modalities, the RAS targeting therapies market is anticipated to witness steady growth over the next decade

GLOBAL KRAS MARKET: KEY INSIGHTS

The report delves into the current state of global KRAS market and identifies potential growth opportunities within industry. Some key findings from the report include:

Presently, several companies claim to be engaged in the development of novel drug candidates for the treatment of various cancers originating due to RAS mutations.
Most of the drug candidates are being evaluated in early stages of development, either as monotherapies or in combination with other products, for delivery via different administration routes.
Over 70% of the therapies are being evaluated across preclinical and clinical stages, either as monotherapies or in combination with other products. Majority of the RAS targeting therapies (79%) are designed for administration via the oral route.

In pursuit of gaining a competitive edge, firms located in different regions are actively investing, in terms of both resources and capital, to conduct R&D of their proprietary products.
Over the years, there has been significant increase in number of clinical trials related to this novel class of therapies, across different geographies.
Clinical research activity, in terms of the number of trials registered, is reported to have increased at a CAGR of 5%, in the past three years. Of the total number of trials, close to 25% of the studies have already been completed, while 60% are active and still recruiting patients.
In recent years, a large number of companies have recently entered into strategic collaborations for the development of novel small molecule candidates.
Majority of the deals were reported to be product licensing agreements, representing over 30% of the total number of instances.
Foreseeing lucrative returns, many public and private investors have made investments across several funding rounds, in the last five years.
Of the total, close to USD 600 million was raised through venture capital financing, representing around 40% of the overall share. On the other hand, over 5 instances of IPOs / secondary offerings were reported, wherein players collectively raised more than USD 775 million in financing.
Both industry players and academic institutes have made significant contributions towards expanding the pool of published scientific literature; past and ongoing studies were focused on treatment of cancer indications.
Majority of the authors affiliated with deemed universities have published articles focused on KRAS (80%), in the last year.
In the past years, there has been an exponential increase in the number of publications, including research articles focused on RAS targeting therapies.
Published articles / papers indicate that the current research activity is focused on targeting RAS isoforms, primarily mutated KRAS gene.
Majority of the publications are focused on RAS targeting therapies intended for colorectal cancer, lung cancer and pancreatic cancer.
In order to adequately monetize their proprietary offerings, drug developers are actively exploring diverse commercialization strategies across various stages of a product's launch cycle.
Driven by the growing cancer burden and rising need for targeted drug therapies, the RAS targeted therapies market is projected to grow at a lucrative rate over the coming decade.
The overall market opportunity is likely to be distributed across different types of therapies and routes of administration.

Example Players in the KRAS Market

Amgen
GlobeImmune
Jacobio Pharmaceuticals
Mirati Therapeutics
Novartis
Onconova Therapeutics
Targovax
Verastem Oncology.

GLOBAL KRAS MARKET

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global KRAS market, focusing on key market segments, including [A] type of indication, [B] type of molecule, [C] type of therapy, [D] route of administration and [E] key geographical regions.
Market Landscape: A comprehensive evaluation of RAS targeting therapies, considering various parameters, such as [A] current status of development, [B] phase of development, [C] type of molecule, [D] type of therapy, [E] target therapeutic area, [F] target gene, [G] line of treatment and [H] route of administration. Additionally, the section includes a comprehensive evaluation of companies engaged in the development of RAS targeting therapies, based on several relevant parameters, such as [A] year of establishment, [B] employee count and [C] geographical presence.
Clinical Trial Analysis: An in-depth analysis of clinical trials of various RAS targeting therapies, based on several relevant parameters, such as [A] trial registration year, [B] trial phase, [C] trial recruitment status, [D] enrolled patient population, [E] study design, [F] leading industry sponsors / collaborators, [G] trial focus, [H] target indication, [I] most popular indications and [J] regional distribution of trials.
Product Competitiveness Analysis: An insightful competitive analysis of key players engaged in KRAS market (on the basis of the strength of their respective development portfolios), examining factors, such as [A] company size and [B] stage of development of lead molecules.
Company Profiles: In-depth profiles of companies engaged in offering RAS targeting therapies, focusing on [A] company overview, [B] product portfolio and [C] recent developments and an informed future outlook.
Publication Analysis: A comprehensive analysis of close to 1,600 peer-reviewed scientific articles related to research on RAS targeting therapies, based on [A] year of publication, [B] focus areas, [C] type of molecule, [D] popular keywords and [E] key journals.
Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in this domain, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of molecule, [D] most active players (in terms of the number of partnerships signed) and [E] geographical distribution of partnership activity.
Funding and Investments: An in-depth analysis of various investments, such as [A] venture capital financing, [B] debt financing, [C] grants / awards, [D] capital raised from IPOs and [E] subsequent offerings that were undertaken by players engaged in KRAS market.
Key Commercialization Strategies: A detailed discussion on the various commercialization strategies that have been adopted by drug developers engaged in KRAS market across different stages of therapy development, including pre-drug launch, at / during drug launch and post-marketing stage.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RA100292

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
- 1.2.1. Research Assumptions
- 1.2.2. Project Methodology
- 1.2.3. Forecast Methodology
- 1.2.4. Robust Quality Control
- 1.2.5. Key Considerations
  - 1.2.5.1. Demographics
  - 1.2.5.2. Economic Factors
  - 1.2.5.3. Government Regulations
  - 1.2.5.4. Supply Chain
  - 1.2.5.5. COVID Impact / Related Factors
  - 1.2.5.6. Market Access
  - 1.2.5.7. Healthcare Policies
  - 1.2.5.8. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Overview of RAS Targeting Therapies
3.2. Approaches Used to Target Mutated RAS Gene
3.3. Historical Notable Developments
3.4. Prominent Gene Driver Related Mutations in RAS Mutated Cancers
3.5. Challenges and Future Perspectives Associated with Treatment of RAS Mutated Cancers

4. CURRENT MARKET LANDSCAPE

4.1. RAS Targeting Therapies: Pipeline Review
- 4.1.1. Analysis by Phase of Development
- 4.1.2. Analysis by Route of Administration
- 4.1.3. Analysis by Line of Treatment
- 4.1.4. Analysis by Type of Therapy
- 4.1.5. Analysis by Type of Molecule
- 4.1.6. Analysis by Target Gene
- 4.1.7. Analysis by Target Therapeutic Area
- 4.1.8. Analysis by Phase of Development and Leading Players
4.2. RAS Targeting Therapies: Developer Landscape
- 4.2.1. Analysis by Year of Establishment
- 4.2.2. Analysis by Company Size
- 4.2.3. Analysis by Location of Headquarters
- 4.2.4. Analysis by Geography

5. CLINICAL TRIALS AND ENDPOINT ANALYSIS

5.1. RAS Targeting Therapies: List of Clinical Trials
- 5.1.1. Analysis by Trial Status
- 5.1.2. Analysis by Trial Registration Year
- 5.1.3. Analysis by Type of Masking
- 5.1.4. Analysis by Type of Intervention Model
- 5.1.5. Analysis by Study Design
- 5.1.6. Analysis by Type of Sponsor
- 5.1.7. Most Active Players: Analysis by Number of Trials Registered
- 5.1.8. Analysis by Trial Registration Year and Geography
- 5.1.9. Analysis by Type of Target Indication
- 5.1.10. Analysis by Enrolled Patient Population
- 5.1.11. Analysis of Enrolled Patient Population by Geography
- 5.1.12. Analysis of Number of Clinical Trials by Geography

6. PRODUCT COMPETITIVENESS ANALYSIS

6.1. Product Competitiveness: North America
6.2. Product Competitiveness: Europe
6.3. Product Competitiveness: Asia-Pacific

7. COMPANY PROFILES

7.1. Amgen
- 7.1.1. Company Overview
- 7.1.2. Financial Information
- 7.1.3. Portfolio of RAS Targeting Therapies
- 7.1.4. Recent Developments and Future Outlook
7.2. GlobeImmune
- 7.2.1. Company Overview
- 7.2.2. Financial Information
- 7.2.3. Portfolio of RAS Targeting Therapies
- 7.2.4. Recent Developments and Future Outlook
7.3. Jacobio Pharmaceuticals
- 7.3.1. Company Overview
- 7.3.2. Financial Information
- 7.3.3. Portfolio of RAS Targeting Therapies
- 7.3.4. Recent Developments and Future Outlook
7.4. Mirati Therapeutics
- 7.4.1. Company Overview
- 7.4.2. Financial Information
- 7.4.3. Portfolio of RAS Targeting Therapies
- 7.4.4. Recent Developments and Future Outlook
7.5. Novartis
- 7.5.1. Company Overview
- 7.5.2. Financial Information
- 7.5.3. Portfolio of RAS Targeting Therapies
- 7.5.4. Recent Developments and Future Outlook
7.6. Onconova Therapeutics
- 7.6.1. Company Overview
- 7.6.2. Financial Information
- 7.6.3. Portfolio of RAS Targeting Therapies
- 7.6.4. Recent Developments and Future Outlook
7.7. Targovax
- 7.7.1. Company Overview
- 7.7.2. Financial Information
- 7.7.3. Portfolio of RAS Targeting Therapies
- 7.7.4. Recent Developments and Future Outlook
7.8. Verastem Oncology
- 7.8.1. Company Overview
- 7.8.2. Financial Information
- 7.8.3. Portfolio of RAS Targeting Therapies
- 7.8.4. Recent Developments and Future Outlook

8. PUBLICATION ANALYSIS

8.1. RAS Targeting Therapies: Recent Publications
- 8.1.1. Analysis by Year of Publication
- 8.1.2. Analysis by Type of Publication
- 8.1.3. Analysis by Study Objective
- 8.1.4. Analysis by Emerging Focus Areas
- 8.1.5. Analysis by Target Therapeutic Area
- 8.1.6. Analysis by Target Gene
- 8.1.7. Analysis by Target Indication
- 8.1.8. Analysis by Affiliation of First Author
- 8.1.9. Leading Players: Analysis by Number of Publications
- 8.1.10. Key Journals: Analysis by Number of Publications

9. PARTNERHSIPS AND COLLABORATIONS

9.1. RAS Targeting Therapies: List of Partnerships and Collaborations
- 9.1.1. Analysis by Year of Partnership
- 9.1.2. Analysis by Type of Partnership
- 9.1.3. Analysis by Type of Partner
- 9.1.4. Analysis by Type of Molecule
- 9.1.5. Most Active Players: Analysis by Number of Partnerships
- 9.1.6. Most Active Partners: Analysis by Number of Partnerships
- 9.1.7. Regional Analysis
- 9.1.8. Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS

10.1. RAS Targeting Therapies: Funding and Investments
- 10.1.1. Analysis by Number of Funding Instances
- 10.1.2. Analysis by Amount Invested
- 10.1.3. Analysis by Type of Funding
- 10.1.4. Most Active Players: Analysis by Amount Raised
- 10.1.5. Most Active Investors: Analysis by Number of Instances
- 10.1.6. Analysis by Geography

11. KEY COMMERCIALIZATION STRATEGIES

11.1. Successful Drug Launch Strategy: ROOTS Framework
11.2. Successful Drug Launch Strategy: Product Differentiation
11.3. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
11.4. Key Commercialization Strategies Adopted by Companies Focused on RAS Targeting Therapies
- 11.4.1. Strategies Adopted Before Therapy Approval
11.5. Strategies Adopted During / Post Therapy Approval
11.6. Analysis by Ease of Implementation, Value Addition and Current Adoption (Harvey Ball Framework)

12. MARKET SIZING AND OPPORTUNITY ANALYSIS

12.1. Forecast Methodology and Key Assumptions
12.2. Global RAS Targeting Therapies Market, Till 2035
12.3. Global RAS Targeting Therapies Market, Till 2035: Distribution by Target Indication
12.4. Global RAS Targeting Therapies Market, Till 2035: Distribution by Type of Molecule
12.5. Global RAS Targeting Therapies Market, Till 2035: Distribution by Type of Therapy
12.6. Global RAS Targeting Therapies Market, Till 2035: Distribution by Route of Administration
12.7. Global RAS Targeting Therapies Market, Till 2035: Distribution by Geography
12.8. RAS Targeting Therapies: Individual Product Sales Forecasts
- 12.8.1. LUMAKRASTM (Amgen): Sales Forecast
- 12.8.2. Adagrasib (Mirati Therapeutics): Sales Forecast
- 12.8.3. AMO-01 (AMO Pharma): Sales Forecast
- 12.8.4. Antroquinonol (Golden Biotech): Sales Forecast
- 12.8.5. Binimetinib (Array Biopharma): Sales Forecast
- 12.8.6. CH7126766/VS6766 (Verastem Oncology): Sales Forecast
- 12.8.7. LXH274 (Novartis): Sales Forecast
- 12.8.8. Rigosertib (Onconova Therapeutics): Sales Forecast
- 12.8.9. RMC-4630 (Revolution Medicine): Sales Forecast
- 12.8.10. TG01 (Targovax): Sales Forecast
- 12.8.11. Tipifarnib (Kura Oncology): Sales Forecast
- 12.8.12. siG12D (Silenseed): Sales Forecast

13. CONCLUSION

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Product Code: RA100292

List of Tables

Table 4.1 RAS Targeting Therapies: List of Industry and Non-Industry Players
Table 5.1 RAS Targeting Therapies: List of Clinical Trials
Table 8.1 RAS Targeting Therapies: List of Recent Publications
Table 9.1 RAS Targeting Therapies: List of Partnerships and Collaborations
Table 10.1 RAS Targeting Therapies: List of Funding and Investments
Table 14.1 RAS Targeting Therapies: Distribution by Phase of Development
Table 14.2 RAS Targeting Therapies: Distribution by Route of Administration
Table 14.3 RAS Targeting Therapies: Distribution by Line of Treatment and Type of Therapy
Table 14.4 RAS Targeting Therapies: Distribution by Type of Molecule
Table 14.5 RAS Targeting Therapies: Distribution by Phase of Development and Type of Molecule
Table 14.6 RAS Targeting Therapies: Distribution by Type of Molecule and Route of Administration
Table 14.7 RAS Targeting Therapies: Distribution by Target Gene and Target Indication
Table 14.8 Most Active Players: Distribution by Number of Trials Registered
Table 14.9 RAS Targeting Therapy Developers: Distribution by Year of Establishment
Table 14.10 RAS Targeting Therapy Developers: Distribution by Company Size
Table 14.11 RAS Targeting Therapy Developers: Distribution by Location of Headquarters
Table 14.12 RAS Targeting Therapy Developers: Distribution by Geography
Table 14.13 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year
Table 14.14 Clinical Trial Analysis: Distribution by Type of Masking and Intervention Model Adopted
Table 14.15 Clinical Trial Analysis: Distribution by Study Design and Trial Status
Table 14.16 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 14.17 Most Active Players: Distribution by Number of Clinical Trials
Table 14.18 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Table 14.19 Clinical Trial Analysis: Distribution by Target Indication
Table 14.20 Clinical Trial Analysis: Distribution of Number of Trials by Geography
Table 14.21 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patients Population
Table 14.22 Clinical Trial Analysis: Distribution by Geography, Patients Enrolled and Trial Status
Table 14.23 Clinical Trial Analysis: Distribution by Patients Enrolled and Phase of Development
Table 14.24 Product Competitiveness Analysis: North America Scenario
Table 14.25 Product Competitiveness Analysis: Europe Scenario
Table 14.26 Product Competitiveness Analysis: Asia-Pacific Scenario
Table 14.27 Amgen: Financial Information
Table 14.28 GlobeImmune: Financial Information
Table 14.29 Jacobio Pharmaceuticals: Financial Information
Table 14.30 Mirati Therapeutics: Financial Information
Table 14.31 Novartis: Financial Information
Table 14.32 Onconova Therapeutics: Financial Information
Table 14.33 Targovax: Financial Information
Table 14.34 Verastem Oncology: Financial Information
Table 14.35 Publication Analysis: Distribution by Year of Publication
Table 14.36 Publication Analysis: Distribution by Type of Publication
Table 14.37 Publication Analysis: Distribution by Study Objective
Table 14.38 Publication Analysis: Distribution by Emerging Focus Area
Table 14.39 Publication Analysis: Distribution by Target Gene
Table 14.40 Publication Analysis: Distribution by Target Therapeutic Area
Table 14.41 Publication Analysis: Distribution by Target Indication
Table 14.42 Publication Analysis: Distribution by Affiliation of First Author
Table 14.43 Most Active Players: Distribution by Number of Publications
Table 14.44 Key Journals: Distribution by Number of Publications
Table 14.45 Partnerships and Collaborations: Distribution by Year of Partnership
Table 14.46 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.47 Partnerships and Collaborations: Distribution by Type of Partner
Table 14.48 Partnerships and Collaborations: Distribution by Type of Molecule
Table 14.49 Most Active Players: Distribution by Number of Partnerships
Table 14.50 Most Active Partners: Distribution by Number of Partnerships
Table 14.51 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 14.52 Funding and Investment Analysis: Cumulative Year-wise Distribution by Amount Invested, Since 2016
Table 14.53 Funding and Investment Analysis: Distribution by Type of Funding
Table 14.54 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 14.55 Funding and Investment Analysis: Distribution by Year, Amount Invested and Type of Funding, Since 2016 (USD Million)
Table 14.56 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 14.57 Key Investors: Distribution by Number of Funding Instances
Table 14.58 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Table 14.59 Key Commercialization Strategies: Harvey Ball Analysis
Table 14.60 Successful Drug Launch Strategy: ROOTS Framework
Table 14.61 Historical Strategies Adopted by the Developer of LUMAKRAS(TM)
Table 14.62 Successful Drug Launch Strategy: Product Differentiation
Table 14.63 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
Table 14.64 Harvey Ball Analysis: Commercialization Strategies Adopted by RAS Targeting Therapy Developers
Table 14.65 RAS Targeting Therapies Market, Till 2035 (USD Million)
Table 14.66 RAS Targeting Therapies Market: Distribution by Type of Molecule / Drug Class (USD Million)
Table 14.67 RAS Targeting Therapies Market: Distribution by Type of Therapy (USD Million)
Table 14.68 RAS Targeting Therapies Market: Distribution by Route of Administration (USD Million)
Table 14.69 RAS Targeting Therapies Market: Distribution by Location of Headquarters (USD Million)
Table 14.70 LUMAKRAS(TM) (Amgen): Estimated Sales, Till 2035 (USD Million)
Table 14.71 Adagrasib (Mirati Therapeutics): Estimated Sales, Till 2035 (USD Million)
Table 14.72 AMO-01 (AMO Pharma): Estimated Sales, Till 2035 (USD Million)
Table 14.73 Antroquinonol (Golden Biotech): Estimated Sales, Till 2035 (USD Million)
Table 14.74 Binimetinib (Array Biopharma): Estimated Sales, Till 2035 (USD Million)
Table 14.75 CH7146766/VS6766 (Verastem Oncology): Estimated Sales, Till 2035 (USD Million)
Table 14.76 LXH274 (Novartis): Estimated Sales, Till 2035 (USD Million)
Table 14.77 Rigosertib (Onconova Therapeutics): Estimated Sales, Till 2035 (USD Million)
Table 14.78 RMC-4630 (Revolution Medicine): Estimated Sales, Till 2035 (USD Million)
Table 14.79 TG01 (Targovax): Estimated Sales, Till 2035 (USD Million)
Table 14.80 Tipifarnib (Kura Oncology): Estimated Sales, Till 2035 (USD Million)
Table 14.81 siG14D (Silenseed): Estimated Sales, Till 2035 (USD Million)
Table 14.82 RAS Targeting Therapies: Distribution by Target Therapeutic Area
Table 14.83 RAS Targeting Therapies: Distribution by Type of Molecule and Company Size
Table 14.84 RAS Targeting Therapies: Distribution by Company Size and Region
Table 14.85 Most Active Players: Distribution by Number of Products
Table 14.86 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 14.87 Clinical Trial Analysis: Distribution by Phase of Development, Year and Number of Patients
Table 14.88 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Region
Table 14.89 Clinical Trial Analysis: Distribution by Primary Purpose
Table 14.90 Funding and Investment Analysis: Cumulative Number of Funding Instances by Year, Since 2016
Table 14.91 Funding and Investment Analysis: Cumulative Amount Invested, Since 2016 (USD Million)
Table 14.92 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding, Since 2016
Table 14.93 Funding and Investment Analysis: Distribution of Funding Instances by Geography
Table 14.94 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding, Since 2016
Table 14.95 Most Active Players: Distribution by Number of Funding Instances, Since 2016
Table 14.96 Funding and Investment Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding, Since 2016

List of Figures

Figure 3.1 Approaches for Targeting Mutated RAS Gene
Figure 3.2 Notable Developments within the RAS Targeting Therapies Domain
Figure 3.3 Prominent Gene Driver related Mutations in RAS Mutated Cancers
Figure 3.4 Key Challenges Associated with Targeting and Treatment of RAS Mutated Cancers
Figure 3.5 Future Perspectives of RAS Targeting Therapies
Figure 4.1 RAS Targeting Therapies: Distribution by Phase of Development
Figure 4.2 RAS Targeting Therapies: Distribution by Route of Administration
Figure 4.3 RAS Targeting Therapies: Distribution by Line of Treatment and Type of Therapy
Figure 4.4 RAS Targeting Therapies: Distribution by Type of Molecule
Figure 4.5 RAS Targeting Therapies: Distribution by Phase of Development and Type of Molecule
Figure 4.6 RAS Targeting Therapies: Distribution by Type of Molecule and Route of Administration
Figure 4.7 RAS Targeting Therapies: Distribution by Target Gene and Target Indication
Figure 4.8 Most Active Players: Distribution by Number of Trials Registered
Figure 4.9 RAS Targeting Therapy Developers: Distribution by Year of Establishment
Figure 4.10 RAS Targeting Therapy Developers: Distribution by Company Size
Figure 4.11 RAS Targeting Therapy Developers: Distribution by Location of Headquarters
Figure 4.12 RAS Targeting Therapy Developers: Distribution by Geography
Figure 5.1 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year
Figure 5.2 Clinical Trial Analysis: Distribution by Type of Masking and Intervention Model Adopted
Figure 5.3 Clinical Trial Analysis: Distribution by Study Design and Trial Status
Figure 5.4 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 5.5 Most Active Players: Distribution by Number of Clinical Trials
Figure 5.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Figure 5.7 Clinical Trial Analysis: Distribution by Target Indication
Figure 5.8 Clinical Trial Analysis: Distribution of Number of Trials by Geography
Figure 5.9 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patients Population
Figure 5.10 Clinical Trial Analysis: Distribution by Geography, Patients Enrolled and Trial Status
Figure 5.11 Clinical Trial Analysis: Distribution by Patients Enrolled and Phase of Development
Figure 6.1 Product Competitiveness Analysis: North America Scenario
Figure 6.2 Product Competitiveness Analysis: Europe Scenario
Figure 6.3 Product Competitiveness Analysis: Asia-Pacific Scenario
Figure 7.1 Amgen: Financial Information
Figure 7.2 GlobeImmune: Financial Information
Figure 7.3 Jacobio Pharmaceuticals: Financial Information
Figure 7.4 Mirati Therapeutics: Financial Information
Figure 7.5 Novartis: Financial Information
Figure 7.6 Onconova Therapeutics: Financial Information
Figure 7.7 Targovax: Financial Information
Figure 7.8 Verastem Oncology: Financial Information
Figure 8.1 Publication Analysis: Distribution by Year of Publication
Figure 8.2 Publication Analysis: Distribution by Type of Publication
Figure 8.3 Publication Analysis: Distribution by Study Objective
Figure 8.4 Publication Analysis: Distribution by Emerging Focus Area
Figure 8.5 Publication Analysis: Distribution by Target Gene
Figure 8.6 Publication Analysis: Distribution by Target Therapeutic Area
Figure 8.7 Publication Analysis: Distribution by Target Indication
Figure 8.8 Publication Analysis: Distribution by Affiliation of First Author
Figure 8.9 Most Active Players: Distribution by Number of Publications
Figure 8.10 Key Journals: Distribution by Number of Publications
Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Molecule
Figure 9.5 Most Active Players: Distribution by Number of Partnerships
Figure 9.6 Most Active Partners: Distribution by Number of Partnerships
Figure 9.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Funding and Investment Analysis: Cumulative Year-wise Distribution by Amount Invested, Since 2016
Figure 10.2 Funding and Investment Analysis: Distribution by Type of Funding
Figure 10.3 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 10.4 Funding and Investment Analysis: Distribution by Year, Amount Invested and Type of Funding, Since 2016 (USD Million)
Figure 10.5 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 10.6 Key Investors: Distribution by Number of Funding Instances
Figure 10.7 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Figure 11.1 Key Commercialization Strategies: Harvey Ball Analysis
Figure 11.2 Successful Drug Launch Strategy: ROOTS Framework
Figure 11.3 Historical Strategies Adopted by the Developer of LUMAKRAS(TM)
Figure 11.4 Successful Drug Launch Strategy: Product Differentiation
Figure 11.5 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
Figure 11.6 Harvey Ball Analysis: Commercialization Strategies Adopted by RAS Targeting Therapy Developers
Figure 12.1 RAS Targeting Therapies Market, Till 2035 (USD Million)
Figure 12.2 RAS Targeting Therapies Market: Distribution by Type of Molecule / Drug Class (USD Million)
Figure 12.3 RAS Targeting Therapies Market: Distribution by Type of Therapy (USD Million)
Figure 12.4 RAS Targeting Therapies Market: Distribution by Route of Administration (USD Million)
Figure 12.5 RAS Targeting Therapies Market: Distribution by Location of Headquarters (USD Million)
Figure 12.6 LUMAKRAS(TM) (Amgen): Estimated Sales, Till 2035 (USD Million)
Figure 12.7 Adagrasib (Mirati Therapeutics): Estimated Sales, Till 2035 (USD Million)
Figure 12.8 AMO-01 (AMO Pharma): Estimated Sales, Till 2035 (USD Million)
Figure 12.9 Antroquinonol (Golden Biotech): Estimated Sales, Till 2035 (USD Million)
Figure 12.10 Binimetinib (Array Biopharma): Estimated Sales, Till 2035 (USD Million)
Figure 12.11 CH7126766/VS6766 (Verastem Oncology): Estimated Sales, Till 2035 (USD Million)
Figure 12.12 LXH274 (Novartis): Estimated Sales, Till 2035 (USD Million)
Figure 12.13 Rigosertib (Onconova Therapeutics): Estimated Sales, Till 2035 (USD Million)
Figure 12.14 RMC-4630 (Revolution Medicine): Estimated Sales, Till 2035 (USD Million)
Figure 12.15 TG01 (Targovax): Estimated Sales, Till 2035 (USD Million)
Figure 12.16 Tipifarnib (Kura Oncology): Estimated Sales, Till 2035 (USD Million)
Figure 12.17 siG12D (Silenseed): Estimated Sales, Till 2035 (USD Million)
Figure 13.1 RAS Targeting Therapies: Distribution by Target Therapeutic Area
Figure 13.2 RAS Targeting Therapies: Distribution by Type of Molecule and Company Size
Figure 13.3 RAS Targeting Therapies: Distribution by Company Size and Region
Figure 13.4 Most Active Players: Distribution by Number of Products
Figure 13.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 13.6 Clinical Trial Analysis: Distribution by Phase of Development, Year and Number of Patients
Figure 13.7 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Region
Figure 13.8 Clinical Trial Analysis: Distribution by Primary Purpose
Figure 13.9 Funding and Investment Analysis: Cumulative Number of Funding Instances by Year, Since 2016
Figure 13.10 Funding and Investment Analysis: Cumulative Amount Invested, Since 2016 (USD Million)
Figure 13.11 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding, Since 2016
Figure 13.12 Funding and Investment Analysis: Distribution of Funding Instances by Geography
Figure 13.13 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding, Since 2016
Figure 13.14 Most Active Players: Distribution by Number of Funding Instances, Since 2016
Figure 13.15 Funding and Investment Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding, Since 2016